73 results about "Metaplasia" patented technology

A system and method for classifying tissue by application of discriminant analysis to spectral data. Spectra are recorded as amplitudes at a series of discrete wavelengths. Pluralities of reference spectra are recorded for specimens having known conditions. The reference spectra are subjected to discriminant analysis to determine wavelength regions of interest for the analysis. A plurality of amplitudes are selected for the analysis, and are plotted in an N-dimensional space. For each plurality of reference spectra corresponding to a specific known condition, a characteristic point is determined and plotted, the characteristic point representative of the known condition. A test spectrum is recorded from a test specimen, and the plurality of amplitudes corresponding in wavelength to the wavelength regions of interest are selected. A characteristic point in N-dimensional space is determined for the test spectrum. The distance of the characteristic point of the test spectrum from each of the plurality of characteristic points representative of known conditions is determined. The test specimen is assigned the condition corresponding to the characteristic point of a plurality of reference spectra, based on a distance relationship with at least two distances, provided that at least one distance is less than a pre-determined maximum distance. In some embodiments, the test specimen can comprise human cervical tissue, and the known conditions can include normal health, metaplasia, CIN I and CIN II / III.

A pharmaceutical preparation suitable for use in the eye, which comprises: (i) a pharmaceutically acceptable carrier suitable for use in the eye; (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and optionally factors and agents to prevent squamous metaplasia; (iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and / or maintaining a stable tear film and optionally one or more agents selected from opthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation; the factors and agents in component (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical use.

Disclosed are methods and kits for assessing risk of progression of Barrett's esophagus to adenocarcinoma.

The invention provides methods for determining the probability that a given region of a tissue sample contains tissue of a given category, such as CIN 1 (cervical intraepithelial neoplasia, grade 1), CIN 2 / 3 (cervical intraepithelial neoplasia grades 2 and / or 3), normal squamous, normal columnar, and metaplasia, for example. The invention provides increased diagnostic accuracy by combining a plurality of statistical classification techniques. Furthermore, in one embodiment, the invention comprises combining one or more statistical techniques with one or more non-statistical classification techniques.

The invention discloses a traditional Chinese medicine composition for treating the stomach diseases and aims at solving the problems that the stomach diseases generally comprise multiple types simultaneously, have the characteristics of diversity and complexity, the western medicine is mainly used for treating the symptoms, and is difficult to treat the stomach diseases thoroughly, but the existing Chinese patent medicine for treating the stomach diseases can not aim at the characteristics of diversity and complexity of the stomach diseases completely to cause no healing for long time and repeated attack of most patients. The traditional Chinese medicine composition comprises pericarpium citri reticulatae viride, pericarpium citri reticulatae, rhizoma cyperi, radix bupleuri, adenophora stricta, pinellia ternata, rhizoma atractylodis macrocephalae, pearl barley, fructus aurantii, mangnolia officinalis and fructus amomi and the like. The traditional Chinese medicine composition disclosed by the invention has the advantages that the effect for treating the stomach diseases is good, the treating effects for multiple stomach diseases (such as stomachache, gastric acid, gastrectasia, acute and chronic gastroenteritis, superficial gastritis, atrophic gastritis, erosive gastritis, gastroenteric ulcer and gastroenteric metaplasia) are good, the difficulties of no healing for long time and repeated attacks of the stomach diseases are thoroughly solved, and the traditional Chinese medicine composition has the characteristics of fast effect, good treating effect, thorough treatment and low possibility of relapse on clinical application and is popular with vast patients.

The invention belongs to the technical field of traditional Chinese medicines and in particular relates to a traditional Chinese medicine composition for treating female infertility and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-10 parts of epimediums, 10-15 parts of semen cuscutae, 10-60 parts of astragalus membranaceus, 5-15 parts of human placenta, 10-15 parts of white atractylodes rhizome, 5-15 parts of angelica, 6-12 parts of ossa sepiae, 5-10 parts of pulp of dogwood fruit, 10-15 parts of fructus lycii, 3-10 parts of scutellaria baicalensis, 6-12 parts of rhizoma cyperi and 3-10 parts of ligusticum wallichii. The traditional Chinese medicine composition has the effects of warming yang, benefiting vital energy, nourishing blood, replenishing essence, regulating vital energy and removing blood stasis; the raw materials are carefully selected, metaplasia of follicle and restoration of reproductive function and organs such as the kidney, the heart, the liver and the spleen are promoted, and a remarkable treatment effect on the female infertility is achieved.

Compounds of formula (I) where A, E, G, X, Y, and the bond --- take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arterosclerosis or restenosis.

This invention publicized one kind to originate from the insect fat body organization, and to the rod-shaped viral high sensitive cell line, this invention has also publicized this cell line establishment method, as well as this cell line the use which grew into the rod-shaped viral scale metaplasia. This cell line may use for to duplicate this kind of virus, uses in the rod-shaped viral pesticide the formalization production, as well as the construction rod-shaped virus the expression vector system, the expression has commercial or the scientific value protein. Therefore it has the extremely high trade and the scientific research value.

The present invention belongs to the field of Chinese herbal medicine, and provides a kind of chronic gastropathy treating Chinese medicine. The Chinese medicine has the functions of invigorating Qi and spleen, warming stomach, nourishing Yin, clearing away heat, keeping the adverse energy downwards, relieving gastric disorder, regulating Qi, etc and is used in treating chronic erosive gastritis, chronic atrophic gastritis, gastric cavity fullness feeling, stomachache and other chronic gastropathy. The present invention has high effective rate.

This invention relates to the use of conjugates of cyanine dyes with an angiogenesis specific binding component preferably with an EB-D fibronectin specific binding component for the diagnosis of micrometastasis and small proliferative lesions, in particular primary tumors, precancerosis, dysplasia, metaplasia, inflammatory lesions, e.g. psoriasis, psoriatic arthritis and / or rheumatoid arthritis, endometriotic lesions, and ocular diseases associated with angiogenesis.

The invention discloses a Chinese medicinal composition, and in particular discloses a Chinese medicinal composition for treating hepatitis B and a preparation method thereof. The Chinese medicinal composition for treating the hepatitis B is characterized by preparing from the following components: astragalus, root of red-rooted salvia, radix bupleuri, szechwon tangshen root, Chinese angelica, Indian buead, shizandra berry, common macrocarpium fruit, large-headed atractylodes rhizome, liquorice root, indigowoad root, cinnamomvine, malt, medicated leaven and hawthorn fruit. The Chinese medicinal composition is specially used for treating the hepatitis B; the medicaments are matched to achieve the effects of tonifying qi-blood, transforming and transporting functional activities of the spleen and stomach normally and completing acquired metaplasia, nourish the congenital liver and kidney to recover the function of various internal organs, and eliminate pathogens to sooth the liver and promote the circulation of qi, eliminate dampness and allay fever, detoxify and promote blood circulation. Over 400 patients are treated, and the effective rate reaches over 91 percent. The special Chinese medicinal composition is used for treating the hepatitis B specially, and has the obvious the curative effect.

The present invention is based on the unexpected discovery that the loss of cells in inflamed tissue during chronic inflammation leads to the influx and long-term re-population of the tissue with bone marrow derived stem cells, and that it is these stem cells that are the primary source of metaplasia and cancer. Accordingly, the invention relates to various methods, reagents and kits for prognosing, diagnosing, staging, monitoring, preventing and treating cancers, particularly cancers associated with chronic inflammation.

The invention described herein relates to the treatment, detection, and diagnosis of various cancers, including esophageal or gastric adenocarcinoma and related metaplasias. The invention also includes a clonal population of Barrett's esophagus progenitor cells and methods of using them for the treatment, detection, and diagnosis of Barrett's esophagus.

The invention relates to porridge for treating chloasma, in particular to traditional Chinese medicine bovine liver porridge for treating chloasma, which takes vegetal Chinese herbal medicines as raw materials. The porridge comprises the following raw materials in parts by weight: 400-600 parts of bovine liver, 50-150 parts of rice, 25-35 parts of loofah, 6 parts of peach kernel, 6 parts of safflower, 8 parts of feverfew, 8 parts of white silkworm, 8 parts of white peony root, 10 parts of poria extract, 10 parts of capillary wormwood herb and 3 parts of raw liquorice. The porridge provided by the invention has the efficacies of dispersing stagnated liver qi, nourishing yin and invigorating the kidney, regulating qi and blood, activating blood circulation to dissipate blood stasis, clearing away heat and toxic materials, relaxing the bowels, removing freckles and acnes, moisturizing the skin and the like; and the porridge is mainly used for treating chloasma caused by disorder of qi and blood on face resulting from liver dysfunction, stagnation of liver qi, liver fire caused by long-time stagnation, impairment to yin and blood, blood stasis, deficiency of spleen qi, dysfunction of the spleen in transportation and failure in essence metaplasia.

The invention discloses a JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and a preparation method and application thereof. The compound has a structure shown in general formula (I) or (II), and the invention provides a specific preparation method of the compound and application of the compound in preventing or treating inflammation, tumor and blood related diseases; the inflammation, tumor and blood related diseases include psoriasis, rheumatic arthritis, polycythemia vera, cicatricial alopecia, primary thrombocythemia, ulcerative colitis, myelofibrosis with myeloid metaplasia, severe combined immune deficiency, various leukemia, various solid tumors and the like.

The invention relates to a traditional Chinese medicine composition for treating hypothermia in sows. The ingredients and parts by weight are as follows: Codonopsis 15-25 parts, Radix Astragali 10-20 parts, Aconite 10-20 parts, Atractylodes macrocephala 10-20 parts, Angelica sinensis 15-25 parts 10-20 parts of dried ginger, 10-15 parts of Chuanxiong, 10-15 parts of amomum, 10-15 parts of cinnamon, 5-15 parts of licorice, and 1 jujube / 146 grams. The treatment principle of sow hypothermia involved in the present invention should be based on raising the temperature. The traditional Chinese medicine provided by the present invention has the characteristics of invigorating the spleen and stomach, generating qi and blood, warming the meridians, exuberant qi and blood, and recovering body temperature. Although heat has the disadvantage of restraining the fetus, the combination of amomum and atractylodes macrocephala has the effect of calming the fetus and invigorating the spleen, so that it can be restrained, the mother can be healthy, and the fetus will be safe and sound.

Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines. The compositions and methods may be useful for the treatment of an airway disorder such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), allergic disorders, pulmonary inflammatory diseases, pulmonary fibrosis, and / or interstitial lung diseases.

The present invention is based on the unexpected discovery that the loss of cells in inflamed tissue during chronic inflammation leads to the influx and long-term re-population of the tissue with bone marrow derived stem cells, and that it is these stem cells that are the primary source of metaplasia and cancer. Accordingly, the invention relates to various methods, reagents and kits for prognosing, diagnosing, staging, monitoring, preventing and treating cancers, particularly cancers associated with chronic inflammation.

The invention discloses a medicament for treating a gastrointestinal disease. The medicament comprises the following medicinal materials serving as active ingredients: 3 to 6g of cutch, 3 to 6g of gallnut, 3 to 6g of dragon's blood, 3 to 10g of costustoot, 6 to 9g of beautyberry and 1 to 3g of centipede. A composition consisting of the medicinal materials can effectively treat the gastrointestinal disease; and the medicinal materials are common medicinal materials, have low price, can be used as an oral preparation in clinical use and can be directly and orally taken in the form of powder composition or orally taken in the form of capsules. The medicament is suitable for treating esophagitis, gastric ulcer, gastric erosion, gastric perforation, gastric bleeding, gastrointestinal polyp, gastrointestinal metaplasia, gastratrophy, helicobacter pylori and gastric cancer and can help recovery after surgeries of gastric cancer and intestinal cancer.

The invention relates to a medicament for treating acute gouty arthritis and a preparation method thereof. The medicament is characterized in that: the medicament comprises the following Chinese medicinal components in part by weight: 4 to 7 parts of swordlike atractylodes rhizome, 6 to 9 parts of Mongolian dandelion herb, 5 to 8 parts of honeysuckle flower, 6 to 9 parts of gypsum, 4 to 7 parts of ginseng, 5 to 8 parts of Chinese flowering quince, 4 to 7 parts of cinnamomvine, 6 to 9 parts of coix seed, 6 to 9 parts of talc, 3 to 6 parts of common lophatherum herb, 3 to 6 parts of anemarrhena, 2 to 4 parts of agaric, 6 to 9 parts of glabrous greenbrier rhizome, 5 to 8 parts of hiraute shiny bugleweed herb, 0.3 to 0.6 part of mix-fried nux vomica and 6 to 9 parts of dahurian patrinia herb.The Chinese medicinal components are used together and have the collaborative and complementary effects of excreting dampness and expelling turbidity, clearing heat and detoxicating, dissolving stasis and relieving pain, stopping mutual metaplasia of damp-heat noxious blood stasis, and ending pathological links. The medicament has a total effective rate of 93 percent.

The present invention is directed to aminobenzimidazole derivative compounds and compositions comprising thereof. The present invention also relates to uses of these compounds to treat or prevent several conditions including neoplasia, dysplasia, metaplasia, and cancer.

A method for constructing a xerophthalmia model in vitro relates to a xerophthalmia model. A method for constructing a xerophthalmia model in vitro with easy operation, good repeatability, lower cost than animal model and a plurality of similar histopathological characteristics similar to xerophthalmia and application thereof in simulating, studying and preventing xerophthalmia are provided. The conjunctiva tissue containing conjunctival epithelium and conjunctival submucosa is cut and placed in culture media; the conjunctiva tissue is trimmed into a conjunctiva tissue block which is placed on a culture vessel inserter coated by type I collagen, with conjunctival epithelium being upward; the culture media are added into the culture vessel outside the inserter to cause the gas-liquid interface of the culture media to be at the junction of the conjunctival epithelium and conjunctival submucosa of the conjunctiva tissue block; and the conjunctiva tissue block is placed into a culture tank to be cultured. The xerophthalmia model in vitro can be used for such researches as xerophthalmia squamous epithelium metaplasia, ocular surface epithelial barrier breakdown, ocular surface epithelial mucoprotein change, and function of the participation and atopsis of inflammatory mediator in xerophthalmia diseases in the generation and development of xerophthalmia.

The present invention relates to Psoralca corylifolia and new application of its fat-soluble portion in medicine. They have obvious action for resisting helicobacter pylori (Hp), and can be used for curing the diseases of gastritis and peptide gastric ulcer, etc. resulted from helicobacter pylori infection, in particular, they are good therapeutic effect for curing active gastritis, gastric erosion, gastric ulcer and duodenal ulcer, and have the action for curing and preventing the diseases of gastric lymph tissue (MALT) lymphoma and early gastric cancer, moderate intestinal glands metaplasia or atypical hyperplasia.

The disclosure provides methods for identifying genomic loci that are differentially / methylated in neoplastic cancers, e.g., esophageal cancers. Identification of methylated genomic loci, and optionally in combination with the identification of somatic mutations in TP53, has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal neoplasias.

The invention relates to a traditional Chinese medicine for treating atrophic gastritis. The medicine is characterized by being prepared from the following raw materials: rhizoma zingiberis, codonopsis pilosula, poria cocos, rhizoma corydalis, panax notoginseng, cuttlebone, radix pseudostellariae, endothelium corneum gigeriae galli, coix seeds, dandelion, selfheal, garden burnet, rhizoma cimicifugae, oysters, turtle shells, ginseng, watermelon seeds, medicated leaven, eclipta, Indian iphigenia bulbs and pumpkin seeds. The medicine is used for treating the atrophic gastritis caused by helicobacter pylori infection, a poor dietary habit, genetic factors, superficial gastritis development and the like, accompanied with symptoms such as a stomach swelling pain, heart burn, vomiting, haematemesis, dyspepsia, fecal abnormality and anemia, protects a stomach mucous membrane, improves intestinal epidermic metaplasia and therefore achieves the purposes of alleviation and curing through warming the middle-jiao, dispelling cold, strengthening the spleen and the stomach, promoting blood circulation, dissipating blood stasis, tonifying qi, promoting production of body fluid, nourishing yin and clearing away heat in company with astringency, hemostasis, swelling diminishing and stasis removal. The medicine is a pure traditional Chinese medicine preparation, is free from chemical ingredients and any hormone, has no side effect, is convenient to take, easy to absorb and low in price and takes effect quickly.

The invention belongs to the technical field of medicines for treating asthma, and particularly relates to application of polygonatum odoratum polysaccharide in preparation of medicines for treating asthma. Experimental research finds that the polygonatum odoratum polysaccharide can improve release of allergic asthma related cell factors in an airway, reduce the number of eosinophilic granulocytes, reduce serum total IgE, improve allergy conditions and improve pathological conditions such as lung inflammatory infiltration, goblet cell metaplasia and pulmonary parenchyma of asthma mice. Therefore, the polygonatum odoratum polysaccharide can be used for preparing the medicine for treating asthma.

The invention discloses a predictive marker, a predictive model and a predictive system for bronchial lung dysplasia of a premature infant. EUGR, caffeine treatment days, total oxygen uptake days and LMR are independent risk factors of BPD occurrence of the premature infant. The lung ultrasound prompts the occurrence rate of the severe alveolar interstitial syndrome on the third day after the premature infant is born, the lung ultrasound prompts the pleural line change on the 28th day after the premature infant is born, and the occurrence rate of the alveolar interstitial syndrome, the pulmonary metaplasia or the fragment symptom has a prediction effect on the occurrence of the BPD. The serum eNOS level of a child patient in a BPD group on the first day after birth is remarkably higher than that of a child patient in a non-BPD group and is in positive correlation with the severity of BPD, and when the serum eNOS level of the child patient on the first day after birth is larger than 6.48 ng / ml, the risk that a premature infant suffers from BPD is obviously increased. The BPD occurrence of the premature infant can be well predicted by constructing a regression model through combination of six indexes, namely the serum eNOS (1d) level, the severe alveolar interstitial syndrome (3d), EUGR, caffeine treatment days, the total oxygen uptake days and LMR6 indexes.